New potential for enhancing concomitant chemoradiotherapy with FDA approved concentrations of cisplatin via the photoelectric effect.
Fiche publication
Date publication
février 2015
Journal
Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics (AIFB)
Auteurs
Membres identifiés du Cancéropôle Est :
Dr DETAPPE Alexandre
Tous les auteurs :
Altundal Y, Cifter G, Detappe A, Sajo E, Tsiamas P, Zygmanski P, Berbeco R, Cormack RA, Makrigiorgos M, Ngwa W
Lien Pubmed
Résumé
We predict, for the first time, that by using United States Food and Drug Administration approved concentrations of cisplatin, major radiosensitization may be achieved via photoelectric mechanism during concomitant chemoradiotherapy (CCRT). Our analytical calculations estimate that radiotherapy (RT) dose to cancer cells may be enhanced via this mechanism by over 100% during CCRT. The results proffer new potential for significantly enhancing CCRT via an emerging clinical scenario, where the cisplatin is released in-situ from RT biomaterials loaded with cisplatin nanoparticles.
Mots clés
Brachytherapy, Chemoradiotherapy, Cisplatin nanoparticles, Dose enhancement, Radiotherapy
Référence
Phys Med. 2015 Feb;31(1):25-30